Section: Bilateral Contracts and Grants with Industry
Contracts and Grants with Industry
Implication in research for the development of Ebola vaccine has lead to several indirect contracts with industry:
-
The EBOVAC1, EBOVAC2 and EBOVAC3 project, collaboration with Janssen from Johnson et Johnson.
-
The Prevac trial vaccine trial leads to collaboration with Merck and Janssen. The purpose of this study is to evaluate the safety and immunogenicity of three vaccine strategies that may prevent Ebola virus disease (EVD) events in children and adults. Participants will receive either the Ad26.ZEBOV (rHAd26) vaccine with a MVA-BN-Filo (MVA) boost, or the rVSVG-ZEBOV-GP (rVSV) vaccine with or without boosting, or placebo. The Prevac-UP project is set as a continuation of Prevac trial in the same framework.